Prostate cancer immunotherapy: the path forward. – UroToday
|
Prostate cancer immunotherapy: the path forward.
UroToday Development of immunotherapy in prostate cancer actually began in 2010 with FDA approval of sipuleucel-T. Given that immune checkpoint inhibitor trials have either been negative at the phase III level or underwhelming in smaller studies, it is likely … |
